LONDON - Oxford BioMedica plc said it achieved positive interim results from Phase I/II trials of MetXia and TroVax, showing the two cancer gene therapy products were safe and prompted clinical improvements in several of those treated. (BioWorld International)
LONDON - Oxford BioMedica plc said it achieved positive interim results from Phase I/II trials of MetXia and TroVax, showing the two cancer gene therapy products were safe and prompted clinical improvements in several of those treated. (BioWorld International)
LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International)
LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International)
